• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR XIENCE SIERRA; DRUG ELUTING CORONARY STENT DELIVERY SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR XIENCE SIERRA; DRUG ELUTING CORONARY STENT DELIVERY SYSTEM Back to Search Results
Catalog Number 1550250-33
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Low Blood Pressure/ Hypotension (1914); Perforation (2001); Thrombosis (2100); Pericardial Effusion (3271)
Event Date 08/16/2019
Event Type  Death  
Manufacturer Narrative
Exemption number: (b)(4)-permits numbering sequence to begin with 10000, to avoid duplication of report numbers due to process transition.There may be gaps in numbering for reports submitted during the transition period.The stent remains in patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.The other additional vascular devices referenced are filed under separate medwatch report numbers.Na.
 
Event Description
It was reported that the patient presented for a staged percutaneous coronary intervention due to a non-st elevated myocardial infarction.The procedure was performed to treat a heavily calcified lesion in the left anterior descending coronary artery.The lesion was prepped with atherectomy and balloon angioplasty.A 2.25 x 38 mm xience sierra stent was implanted distally, and a 2.5 x 33 mm xience sierra stent was implanted proximally; however, following deployment of the 2.5 x 33 mm xience sierra stent, a perforation was noted.Unsuccessful attempts were made to seal the perforation with balloon tamponade and the patient¿s blood pressure started dropping, so a 2.8 x 19 mm graftmaster stent delivery system (sds) was attempted to be advanced, but the shaft kinked and the device was removed without issue.A second 2.8 x 19 mm graftmaster stent was advanced and successfully deployed.Pericardiocentesis was performed to treat the pericardial effusion.Following a non-abbott temporary ventricular assist device was placed and blood clots were noted in the proximal lad, in the graftmaster (due to undersizing) and likely in the proximal 2.5 x 33 mm xience sierra stent.Aspiration of the clots was successfully performed.Due to the heavy calcification, further balloon angioplasty was performed with multiple non-compliant balloon catheters at the site of the graftmaster.Post balloon angioplasty, another perforation was noted.A 4.0 x 19 mm graftmaster stent was deployed to treat this perforation; however, failed to seal the perforation.The balloon of the 4.0 x 19 mm graftmaster stent delivery system (sds) was deflated successfully, but on attempted removal with no reported resistance, it was noted that part of the balloon material had separated with the tip.Attempts to remove the tip of the sds were made with snare and forceps but this was unsuccessful.The balloon migrated to the aorta and the patient lost further pressure and arrested.Cardiopulmonary resuscitation was performed but the patient expired.No additional information was provided.
 
Manufacturer Narrative
Exemption number e2019001-permits numbering sequence to begin with 10000, to avoid duplication of report numbers due to process transition.There may be gaps in numbering for reports submitted during the transition period.The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of perforation, thrombosis, pericardial effusion, hypotension and death are listed in the xience sierra everolimus eluting coronary stent systems instructions for use as a known patient effects of coronary stenting procedures.A medical review was performed by an abbott vascular clinical specialist who concluded that the main cause of death is probably due to perforation (mainly due to the heavy calcified lesion and atherectomy device) and mi.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
XIENCE SIERRA
Type of Device
DRUG ELUTING CORONARY STENT DELIVERY SYSTEM
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
MDR Report Key8978065
MDR Text Key157028642
Report Number2024168-2019-11610
Device Sequence Number1
Product Code NIQ
UDI-Device Identifier08717648227134
UDI-Public08717648227134
Combination Product (y/n)N
PMA/PMN Number
P110019
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Type of Report Initial,Followup
Report Date 10/29/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/09/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date01/28/2020
Device Catalogue Number1550250-33
Device Lot Number9012341
Was Device Available for Evaluation? No
Date Manufacturer Received10/18/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
2.25 X 38 MM XIENCE SIERRA STENT
Patient Outcome(s) Death;
Patient Age85 YR
Patient Weight70
-
-